Synthetic vs. Natural APIs: Key Considerations for Pharmaceutical Manufacturers
Synthetic APIs offer high purity, cost efficiency, and oral stability, while natural APIs face variability and cold-chain challenges. Key trade-offs impact scalability and regulatory compliance.
June 13, 2025
by Nurah Ali
Is the Practice of "Prioritizing Biologics over Small Molecule Drugs" Justified?
The article compares small molecule drugs and biologics in development, cost, etc., questions biologic - preferential policies, and mentions related acts for policy correction.
March 14, 2025
by Krebs Qin
Eleva and 3PBIOVIAN Sign Strategic GMP Manufacturing and Technology Alliance to Boost Capacity for Eleva’s Platform and Pipeline
Eleva and 3PBIOVIAN sign a strategic GMP manufacturing and technology alliance to boost capacity for Eleva's platform and pipeline.
February 5, 2025
by PharmaSources
Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform
Telix completes the acquisition from ImaginAb, getting a drug pipeline and a biologics technology platform.
January 31, 2025
by PRNewswire
Popular APIs of the Year at Pharmasources.com
What are the APIs that caught the highest attention in the year at PharmaSources.com?
December 10, 2024
by PharmaSources
Global Drug Innovation Trend and Its Market Landscape
The creation of novel medications, treatments, and medical equipment that improve patient care and treatment results or outcomes is referred to as pharmaceutical innovation.
September 25, 2024
by Shruti Talashi
Research Progress on the Application of Biologics in Pediatric Asthma
Asthma is a heterogeneous and complex chronic disease. Children with severe asthma often experience acute exacerbations, ultimately leading to impaired lung function and poor quality of life.
July 19, 2024
by Xiaomichong
Common Treatments for Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a chronic inflammatory disorder that primarily affects joints but can also impact other systems in the body, including the skin, eyes, lungs, heart, and blood vessels.
July 1, 2024
by David Orchard-Webb
I-Mab Expands U.S. Footprint with New R&D Site in San Diego
I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that...
October 25, 2021
by prnasia
Eleva Reaches Industrial Production Scale and Prepares for Clinical Development of Factor H
Eleva, a manufacturer of superior biologics, is scaling up its production capacity to 2500 l in state-of-the-art single-use reactors. This will produce enough factor H to cover all three clinical phases.
September 23, 2021
by prnasia
Introduction of FDA Regulatory Education for Industry (REdI) Annual Conference 2021
There are many educational events in FDA throughout the year that focus on the pharmaceutical and regulatory industries.
August 16, 2021
by Lin Zhang
Lumen Bioscience, Google Partner to Apply ML to Biologics Manufacturing
Lumen Bioscience, a clinical-stage biopharma company, announced results from a research collaboration with Google that applied machine learning (ML) to significantly advance the scalability of spirulina-based biologic drugs.
August 12, 2021
by contractpharma